Nonacog Beta Pegol (N9-GP) in Hemophilia B: First Report on Safety and Efficacy in Previously Untreated and Minimally Treated Patients
Real-world Utilisation and Bleed Rates in Patients
with Haemophilia B Who Switched to Recombinant
Factor IX Fusion Protein (rIX-FP): A Retrospective
Real-world Outcomes Associated With Standard Half-life and Extended Half-life Factor Replacement Products for Treatment of Haemophilia A and B
BeneFIX® is a recombinant coagulation FIX. Find out how BeneFIX® works
BeneFIX® provides dosing options based on individual needs
Proven efficacy and protection across dosing regimen
Review efficacy profile
See how BeneFIX® performs in real-life settings.
Review real-world data
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022